74
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Discovery, Characterization, and Structure–Activity Relationships of an Inhibitor of Inward Rectifier Potassium (Kir) Channels with Preference for Kir2.3, Kir3.X, and Kir7.1

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The inward rectifier family of potassium (Kir) channels is comprised of at least 16 family members exhibiting broad and often overlapping cellular, tissue, or organ distributions. The discovery of disease-causing mutations in humans and experiments on knockout mice has underscored the importance of Kir channels in physiology and in some cases raised questions about their potential as drug targets. However, the paucity of potent and selective small-molecule modulators targeting specific family members has with few exceptions mired efforts to understand their physiology and assess their therapeutic potential. A growing body of evidence suggests that G protein-coupled inward rectifier K (GIRK) channels of the Kir3.X subfamily may represent novel targets for the treatment of atrial fibrillation. In an effort to expand the molecular pharmacology of GIRK, we performed a thallium (Tl +) flux-based high-throughput screen of a Kir1.1 inhibitor library for modulators of GIRK. One compound, termed VU573, exhibited 10-fold selectivity for GIRK over Kir1.1 (IC 50 = 1.9 and 19 μM, respectively) and was therefore selected for further study. In electrophysiological experiments performed on Xenopus laevis oocytes and mammalian cells, VU573 inhibited Kir3.1/3.2 (neuronal GIRK) and Kir3.1/3.4 (cardiac GIRK) channels with equal potency and preferentially inhibited GIRK, Kir2.3, and Kir7.1 over Kir1.1 and Kir2.1.Tl + flux assays were established for Kir2.3 and the M125R pore mutant of Kir7.1 to support medicinal chemistry efforts to develop more potent and selective analogs for these channels. The structure–activity relationships of VU573 revealed few analogs with improved potency, however two compounds retained most of their activity toward GIRK and Kir2.3 and lost activity toward Kir7.1. We anticipate that the VU573 series will be useful for exploring the physiology and structure–function relationships of these Kir channels.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome.

          Andersen's syndrome is characterized by periodic paralysis, cardiac arrhythmias, and dysmorphic features. We have mapped an Andersen's locus to chromosome 17q23 near the inward rectifying potassium channel gene KCNJ2. A missense mutation in KCNJ2 (encoding D71V) was identified in the linked family. Eight additional mutations were identified in unrelated patients. Expression of two of these mutations in Xenopus oocytes revealed loss of function and a dominant negative effect in Kir2.1 current as assayed by voltage-clamp. We conclude that mutations in Kir2.1 cause Andersen's syndrome. These findings suggest that Kir2.1 plays an important role in developmental signaling in addition to its previously recognized function in controlling cell excitability in skeletal muscle and heart.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK.

            Mutations in the Na-K-2Cl cotransporter (NKCC2), a mediator of renal salt reabsorption, cause Bartter's syndrome, featuring salt wasting, hypokalaemic alkalosis, hypercalciuria and low blood pressure. NKCC2 mutations can be excluded in some Bartter's kindreds, prompting examination of regulators of cotransporter activity. One regulator is believed to be ROMK, an ATP-sensitive K+ channel that 'recycles' reabsorbed K+ back to the tubule lumen. Examination of the ROMK gene reveals mutations that co-segregate with the disease and disrupt ROMK function in four Bartter's kindreds. Our findings establish the genetic heterogeneity of Bartter's syndrome, and demonstrate the physiologic role of ROMK in vivo.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation.

              The molecular mechanism of increased background inward rectifier current (IK1) in atrial fibrillation (AF) is not fully understood. We tested whether constitutively active acetylcholine (ACh)-activated I(K,ACh) contributes to enhanced basal conductance in chronic AF (cAF). Whole-cell and single-channel currents were measured with standard voltage-clamp techniques in atrial myocytes from patients with sinus rhythm (SR) and cAF. The selective I(K,ACh) blocker tertiapin was used for inhibition of I(K,ACh). Whole-cell basal current was larger in cAF than in SR, whereas carbachol (CCh)-activated I(K,ACh) was lower in cAF than in SR. Tertiapin (0.1 to 100 nmol/L) reduced I(K,ACh) in a concentration-dependent manner with greater potency in cAF than in SR (-logIC50: 9.1 versus 8.2; P<0.05). Basal current contained a tertiapin-sensitive component that was larger in cAF than in SR (tertiapin [10 nmol/L]-sensitive current at -100 mV: cAF, -6.7+/-1.2 pA/pF, n=16/5 [myocytes/patients] versus SR, -1.7+/-0.5 pA/pF, n=24/8), suggesting contribution of constitutively active I(K,ACh) to basal current. In single-channel recordings, constitutively active I(K,ACh) was prominent in cAF but not in SR (channel open probability: cAF, 5.4+/-0.7%, n=19/9 versus SR, 0.1+/-0.05%, n=16/9; P<0.05). Moreover, IK1 channel open probability was higher in cAF than in SR (13.4+/-0.4%, n=19/9 versus 11.4+/-0.7%, n=16/9; P<0.05) without changes in other channel characteristics. Our results demonstrate that larger basal inward rectifier K+ current in cAF consists of increased IK1 activity and constitutively active I(K,ACh). Blockade of I(K,ACh) may represent a new therapeutic target in AF.
                Bookmark

                Author and article information

                Journal
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Research Foundation
                1663-9812
                30 November 2011
                2011
                : 2
                : 75
                Affiliations
                [1] 1simpleDepartment of Anesthesiology, Vanderbilt University School of Medicine Nashville, TN, USA
                [2] 2simpleDepartment of Pharmacology, Vanderbilt University School of Medicine Nashville, TN, USA
                [3] 3simpleVanderbilt Institute of Chemical Biology, Vanderbilt University Nashville, TN, USA
                [4] 4simpleVanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine Nashville, TN, USA
                [5] 5simpleDepartment of Chemistry, Vanderbilt University Nashville, TN, USA
                [6] 6simpleVanderbilt Specialized Chemistry Center for Accelerated Probe Development, Molecular Libraries Probe Production Centers Network Nashville, TN, USA
                Author notes

                Edited by: Ralf Franz Kettenhofen, Axiogenesis AG, Germany

                Reviewed by: Oscar Moran, Institute of Biophysics, National Research Council, Italy; Marcel Van Der Heyden, University Medical Center, Netherlands

                *Correspondence: Jerod S. Denton, Department of Anesthesiology, Vanderbilt University School of Medicine, T4208 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232, USA. e-mail: jerod.s.denton@ 123456vanderbilt.edu

                Rene Raphemot and Daniel F. Lonergan have contributed equally to this work.

                This article was submitted to Frontiers in Pharmacology of Ion Channels and Channelopathies, a specialty of Frontiers in Pharmacology.

                Article
                10.3389/fphar.2011.00075
                3254186
                22275899
                c8a5153b-1794-4360-8be5-fade6508c720
                Copyright © 2011 Raphemot, Lonergan, Nguyen, Utley, Lewis, Kadakia, Weaver, Gogliotti, Hopkins, Lindsley and Denton.

                This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits use, distribution, and reproduction in other forums, provided the original authors and source are credited.

                History
                : 07 October 2011
                : 07 November 2011
                Page count
                Figures: 7, Tables: 1, Equations: 0, References: 59, Pages: 18, Words: 9819
                Categories
                Pharmacology
                Original Research

                Pharmacology & Pharmaceutical medicine
                electrophysiology,pharmacology,fluorescence,thallium flux,girk,high throughput,screening

                Comments

                Comment on this article